Skip to Main Content
hero-about

News

10 Nov '22
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4 th Annual Immunology and Neurology Day and the Stifel
Displaying 1 - 10 of 11